Search

Author/Creator Gils, Ann

21. Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response. Issue 2 (28th February 2021)

Authors:
Outtier, An; Wauters, Lucas; Rahier, Jean‐Francois; Bossuyt, Peter; Colard, Arnaud; Franchimont, Denis; Lambrecht, Guy; Macken, Elisabeth; Van Moerkercke, Wouter; Baert, Filip; Humblet, Evelien; Van Hootegem, Philippe; Gils, Ann; Ferrante, Marc; Vermeire, Séverine
Journal:
GastroHep
Issue:
Volume 3:Issue 2(2021)
Page Start:
63
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

22. Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label. Issue 1 (January 2021)

Authors:
Stefanovic, Sebastian; Detrez, Iris; Compernolle, Griet; Brouwers, Els; Sever, Nejc; Stabuc, Borut; Smrekar, Natasa; Kurent, Tina; Novak, Gregor; Kozelj, Matic; Ferrante, Marc; Gils, Ann; Drobne, David
Journal:
European journal of gastroenterology & hepatology
Issue:
Volume 33:Issue 1(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

23. Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center. Issue 1 (24th October 2019)

Authors:
Bronswijk, Michiel; Moens, Annick; Lenfant, Matthias; Tops, Sophie; Compernolle, Griet; Van Assche, Gert; Vermeire, Séverine; Gils, Ann; Ferrante, Marc
Journal:
Inflammatory bowel diseases
Issue:
Volume 26:Issue 1(2020)
Page Start:
161
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

24. Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center. Issue 4 (10th August 2019)

Authors:
Bronswijk, Michiel; Moens, Annick; Lenfant, Matthias; Tops, Sophie; Compernolle, Griet; Van Assche, Gert; Vermeire, Séverine; Gils, Ann; Ferrante, Marc
Journal:
Inflammatory bowel diseases
Issue:
Volume 26:Issue 4(2020)
Page Start:
628
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

25. Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center. Issue 4 (4th March 2020)

Authors:
Bronswijk, Michiel; Moens, Annick; Lenfant, Matthias; Tops, Sophie; Compernolle, Griet; Van Assche, Gert; Vermeire, Séverine; Gils, Ann; Ferrante, Marc
Journal:
Inflammatory bowel diseases
Issue:
Volume 26:Issue 4(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

26. Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease. (3rd October 2017)

Authors:
Billiet, Thomas; Cleynen, Isabelle; Ballet, Vera; Claes, Karolien; Princen, Fred; Singh, Sharat; Ferrante, Marc; Van Assche, Gert; Gils, Ann; Vermeire, Severine
Journal:
Scandinavian journal of gastroenterology
Issue:
Volume 52:Number 10(2017)
Page Start:
1086
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗